SCHEMBL26906994

SCHEMBL26906994

COc1cc(N2CCC(N3CCN(C)CC3)CC2)c(C)cc1Nc1ncc(Br)c(Nc2cc3c(cc2N(C)S(C)(=O)=O)CCO3)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 19/20 0.61
▸ MET P08581 2/20 0.53
▸ CHEK1 O14757 1/20 0.53
▸ AURKA O14965 1/20 0.53
▸ CCNT1 O60563 1/20 0.53
▸ JAK2 O60674 1/20 0.53
▸ RET P07949 1/20 0.53
▸ ROS1 P08922 1/20 0.53
▸ PDGFRB P09619 1/20 0.53
▸ KIT P10721 1/20 0.53
▸ PIM1 P11309 1/20 0.53
▸ PDGFRA P16234 1/20 0.53
▸ FER P16591 1/20 0.53
▸ EPHA1 P21709 1/20 0.53
▸ MAPK3 P27361 1/20 0.53
▸ EPHB2 P29323 1/20 0.53
▸ AXL P30530 1/20 0.53
▸ MAPK8 P45983 1/20 0.53
▸ CDK9 P50750 1/20 0.53
▸ PKD1 P98161 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26906771 0.97 EGFR (0.58) EGFRMETCHEK1AURKACCNT1
SCHEMBL30860351 0.96 EGFR (0.56) EGFRMETCHEK1AURKACCNT1
SCHEMBL30860239 0.95 EGFR (0.55) EGFRMETCHEK1AURKACCNT1
SCHEMBL30860268 0.94 EGFR (0.65) EGFRMETCHEK1AURKACCNT1
SCHEMBL30860385 0.94 EGFR (0.60) EGFRMETCHEK1AURKACCNT1
SCHEMBL26906950 0.93 EGFR (0.54) EGFRMETCHEK1AURKACCNT1
SCHEMBL30860269 0.93 EGFR (0.58) EGFRMETCHEK1AURKACCNT1
SCHEMBL26906737 0.93 EGFR (0.53) EGFRMETCHEK1AURKACCNT1
SCHEMBL26906830 0.93 EGFR (0.56) EGFRMETPTK2INSRIGF1R
SCHEMBL30860321 0.93 EGFR (0.52) EGFRMETCHEK1AURKACCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US claimed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP claimed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN claimed
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US disclosed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP disclosed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME EGFR, ERBB2, ERBB3 EGFR 1/4885MET 190/4885CHEK1 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback